Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia

Pazopanib (Votrient) is an orally administered tyrosine kinase inhibitor that blocks VEGF receptors potentially serving as anti-angiogenic treatment for hereditary hemorrhagic telangiectasia (HHT). We report a prospective, multi-center, open-label, dose-escalating study [50 mg, 100 mg, 200 mg, and 4...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Angiogenesis
Autors principals: Faughnan, Marie E., Gossage, James R., Chakinala, Murali M., Oh, S. Paul, Kasthuri, Raj, Hughes, Christopher C. W., McWilliams, Justin P., Parambil, Joseph G., Vozoris, Nicholas, Donaldson, Jill, Paul, Gitanjali, Berry, Pamela, Sprecher, Dennis L.
Format: Artigo
Idioma:Inglês
Publicat: Springer Netherlands 2018
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510884/
https://ncbi.nlm.nih.gov/pubmed/30191360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-018-9646-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars